Healthcare
Vicapsys Life Sciences, Inc.(VICP)
Live Price
Offline$1.46
+0.00% today
1Y Change
-17.51%
Window
Jun 23, 2025 → Jun 5, 2026
- Market Cap
- $50.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +32.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vicapsys Life Sciences, Inc. (VICP) is a Healthcare stock with a market cap of $50.00M and listed on OTC. The stock last traded around $1.46 and down 17.5% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +32.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +32.3%, free cash flow +82.4% with operating margin 0.0% and ROIC 16.2%. Stock Foundry combines VICP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +32.3%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VICP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VICP Max Drawdown
-91.53%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VICP and SPY.
Company Overview
Vicapsys Life Sciences, Inc.
Other OTC
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN proprietary product. Its product is applied to transplantation therapies and related stem-cell applications in the transplantation field. The company is also developing VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
- Leadership
- Federico Pier
- IPO Date
- Feb 23, 1998
- Employees
- 2
- Street Address
- 1735 Buford Highway
- Mailing
- Cumming, GA, 30024
- Region
- Cumming, GA, US
- Reporting Currency
- USD
- Investor Line
- 972 891 8033
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- +32.3%
- Free Cash Flow
- +82.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 14.1%
- ROIC
- 16.2%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.